Junshi Biosciences' ongericimab gains approval for expanded use

Shanghai Junshi Biosciences (HKEX: 1877) announced that its supplemental new drug application for Ongericimab injection has been approved by the National Medical Products Administration (NMPA) in China. The approval expands the drug's use to include adult patients with heterozygous familial hypercholesterolemia (HeFH), as well as those with non-familial hypercholesterolemia and mixed dyslipidemia who are statin-intolerant or statins contraindicated, either alone or in combination with ezetimibe.